Proteomic Analysis Identifies p62/SQSTM1 as a Critical Player in PARP Inhibitor Resistance

Proteomic Analysis Identifies p62/SQSTM1 as a Critical Player in PARP Inhibitor Resistance

Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis) are currently being used for treating breast cancer patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative locally advanced or metastatic diseases. Despite durable responses, almost all patients receiving PARPis...

Full description

Bibliographic Details
Main Authors: Mohammed Hafiz Uddin, Jun-Ying Zhou, Julio Pimentel, Steve M. Patrick, Seongho Kim, Malathy P. Shekhar, Gen Sheng Wu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Oncology
Subjects:
PARP inhibitor
resistance
TNBC
p62/SQSTM1
proteomics
autophagy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.908603/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.908603/full

Similar Items